Get the Stockscreener App
27.05
1.65%
0.44
After Hours:
26.90
-0.15
-0.55%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $27.05, with a volume of 52.99M.
It is up +1.65% in the last 24 hours and down -0.62% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$26.61
Open:
$26.54
24h Volume:
52.99M
Relative Volume:
1.13
Market Cap:
$153.81B
Revenue:
$62.58B
Net Income/Loss:
$7.79B
P/E Ratio:
19.96
EPS:
1.3551
Net Cash Flow:
$9.08B
1W Performance:
-2.17%
1M Performance:
-0.62%
6M Performance:
+8.72%
1Y Performance:
+3.09%
1-Day Range:
$26.23
$27.13
1-Week Range:
$26.20
$27.61
52-Week Range:
$20.91
$27.94
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.05 | 151.31B | 62.58B | 7.79B | 9.08B | 1.3551 |
|
LLY
Lilly Eli Co
|
990.33 | 878.04B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
240.40 | 577.48B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
230.11 | 410.83B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
160.12 | 307.23B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
194.22 | 306.31B | 58.80B | 10.24B | 8.98B | 3.2788 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Barclays | Underweight |
| Feb-12-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Here's Why I Wouldn't Touch Regencell Bioscience With a 10‑Foot Pole Right Now - The Motley Fool
Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs - BioPharma Dive
Pfizer Adds New Early-Stage Heart Failure Candidate to Its China Pipeline - TipRanks
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Pfizer stock forecast for 2030. $10B obesity bet and BRAFTOVI approval bets $45 upside - Traders Union
Pfizer (PFE) Gains Approval for Obesity Drug in China - GuruFocus
Pfizer's (PFE) GLP-1 Treatment Gains Approval in China - GuruFocus
Orion Porfolio Solutions LLC Cuts Stake in Pfizer Inc. $PFE - MarketBeat
Edgar Lomax Co. VA Cuts Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Beddow Capital Management Inc. Sells 62,275 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer's Weight Loss Injection GLP-1 Ecnoglutide Injection Approved in CN - AASTOCKS.com
China Greenlights Pfizer’s Obesity Injection as Generic Rivals Approach - FXLeaders
Pfizer Secures China Nod for Obesity Drug as Generics Loom - Bloomberg
China approves Pfizer GLP-1 drug for weight management - Yahoo Finance
China approves Pfizer GLP-1 drug for weight loss - Reuters
Pfizer Gets OK For $29M SEC Payout From Insider Case - Law360
Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund - Reuters
Pfizer’s Comirnaty Update: What U.S. Patients Need To Know Now - AD HOC NEWS
Pfizer Arbitration Confidentiality Rule Is Lawful, NLRB Says - Law360
Smart Money Is Betting Big In PFE Options - Benzinga
Pfizer (PFE) Down 0.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Aerospace Medicine Market is Going to Boom | Major Giants Pfizer, Novartis, Bayer - openPR.com
Retinal Vein Occlusion Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Kodiak Sciences, Roche/Chugai Pharmaceuticals, Novartis, Allergan, Pfizer - Barchart.com
Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations? - TradingView
Pfizer Inc. $PFE Shares Acquired by JT Stratford LLC - MarketBeat
Picton Mahoney Asset Management Acquires Shares of 200,735 Pfizer Inc. $PFE - MarketBeat
Pfizer: Obesity Hype And Vaccine Policy Shocks (NYSE:PFE) - Seeking Alpha
Skeletal Dysplasia Market - GlobeNewswire Inc.
Precision Trading with Pfizer Inc. (PFE) Risk Zones - Stock Traders Daily
Argus Turns Bullish on Pfizer (PFE), Highlights GLP-1 and Oncology Pipeline - Finviz
Pfizer Arbitration Gag Provision Is Lawful, Labor Board Rules - Bloomberg Law News
Pfizer’s Comirnaty update: what US patients really need now - AD HOC NEWS
Celiac Disease Market: Expanding Revenue Landscape to 2034 – DelveInsight | Zedira, Dr. Falk Pharma, Takeda, ImmunoGenX, Provention Bio, Sanofi, Topas Therapeutics GmbH, Pfizer - StreetInsider
Pfizer's Portfolio Renewal In ProgressHigh Yields For The Patient (NYSE:PFE) - Seeking Alpha
Uterine Fibroid Treatment Drugs Market Is Going to Boom Rapidly | - openPR.com
Yeast Infection Treatment Market Is Going to Boom Rapidly | Pfizer Inc., Bayer AG, GlaxoSmithKline plc, Sanofi S.A. - openPR.com
ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP - The Manila Times
Pfizer Inc. $PFE Shares Sold by Mcdonald Partners LLC - MarketBeat
Griffith & Werner Inc. Makes New Investment in Pfizer Inc. $PFE - MarketBeat
GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - GlobeNewswire Inc.
Dimensional Fund Advisors LP Acquires 1,579,117 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. (NYSE:PFE) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Pfizer Inc. (PFE) and Astellas Report Positive Phase 3 EV-304 Results for PADCEV Plus Keytruda in Bladder Cancer - Finviz
Pfizer (NYSE:PFE) Shares Down 2.4%Here's Why - MarketBeat
Pfizer Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Does New Oncology Data Shift The Pipeline-Driven Bull Case For Pfizer (PFE)? - simplywall.st
Pfizer CEO Has ‘A Problem With CBER Leadership’ At US FDA - Citeline News & Insights
Pfizer Advances PF-07328948 Kidney Function Study, Supporting Long-Term Pipeline Value - TipRanks
Pfizer CEO On FDA Vaccines Decisions: ‘We Have A Problem With CBER Leadership’ - Citeline News & Insights
Pfizer stock: Mixed technicals and dividend focus drive a sharp downside move - Traders Union
Pfizer's Quiet Cash Comeback (NYSE:PFE) - Seeking Alpha
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.25%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):